- Citado por SciELO
- Citado por Google
- Similares en SciELO
- Similares en Google
Revista Española de Enfermedades Digestivas
versión impresa ISSN 1130-0108
SOBRINO-COSSIO, Sergio et al. Proton pump inhibitors in gastroesophageal reflux disease: a custom-tailored therapeutic regimen. Rev. esp. enferm. dig. [online]. 2012, vol.104, n.7, pp.367-378. ISSN 1130-0108. http://dx.doi.org/10.4321/S1130-01082012000700006.
The Montreal Definition and Classification divides Gastroesophageal Reflux Disease (GERD) into esophageal symptomatic syndromes (and with mucosal damage) and extraesophageal syndromes (with acid established association and proposed association). In typical GERD symptoms, an 8-week treatment with PPIs is satisfactory in most cases (> 90%). Response rates to PPIs in GERD are highly variable, as they also rely on an appropriate clinical diagnosis of the disease; endoscopy differentiates the macroscopic GERD phenotype. The non-erosive variety (50-70% prevalence) has a different symptomatic response rate, as gastric acid is not the sole etiology of symptoms. The possible explanations of treatment failure include treatment adherence, PPI metabolism alterations and characteristics, and inadequate diagnosis. Refractory symptoms are related to gastric content neutralization by the chronic use of PPIs. Extraesophageal manifestations are associated with other pathophysiological mechanisms where an autonomic nervous system disturbance gives rise to symptoms. In these clinical entities, the relationship between symptoms and acid needs to be established in order to determine the use of PPIs, or consider other drugs. In other words, so as to "custom-tailor the best-fitting therapy" we need to answer the questions for whom, for what, how and for how long. Finally, PPI safety and tolerability are factors to be considered in elderly patients requiring chronic PPI use, who usually have chronic concomitant illnesses.
Palabras clave : GERD; Heartburn (pyrosis); Non-erosive GERD; PPIs; GERD extraesophageal manifestations.